Journal Articles
Permanent URI for this collectionhttps://mro.massey.ac.nz/handle/10179/7915
Browse
9 results
Search Results
Item Surveying cytotoxic chemotherapy use in small animal cancer treatment: insights into use and influencing factors in New Zealand(Taylor and Francis Group on behalf of the New Zealand Veterinary Association, 2025-07-20) Northover S; Hill K; Cogger N; Isaksen KAim: To determine how frequently cytotoxic chemotherapy is administered in small animal practice to treat cancer and the reasons why clinics and clinicians do or do not offer and administer chemotherapy in New Zealand. Methods: A cross-sectional study involving veterinarians working in small and mixed animal practice was performed using an online questionnaire distributed via social media and email. The survey included closed and open-ended questions on respondent demographics, frequency of chemotherapy administration, medications used, cancers treated, and factors influencing administration. Fisher's exact tests were used to assess associations between variables, and content analysis was applied to open-ended responses. Results: Completed questionnaires were returned by 164 veterinarians working in New Zealand during the study period. Of the 164 respondents, 131 (80%) stated that they would probably or definitely discuss cytotoxic chemotherapy with clients as a potential treatment option for small animals with cancer. Within the 12-months preceding July 2023, 56 (34%) respondents had personally administered chemotherapy and 96 (58.5%) worked at clinics where it was administered: 5 (3%) administered it weekly, 6 (4%) at least monthly, 21 (12.8%) every 1–6 months, and 22 (13.4%) every 6–12 months. The most common reason given for administering chemotherapy was to provide comprehensive care to the patient. Improving quality and quantity of life was frequently reported. The most common reason for not administering chemotherapy was referral of cases externally for treatment. Excluding referral, respondents stated they do not administer chemotherapy because of insufficient knowledge regarding chemotherapy and the medications used, or insufficient training in how to handle and administer cytotoxic medications. Of the veterinarians that do not currently perform chemotherapy, 40% and 42% would consider performing it if they had additional education in oncology and chemotherapy, and in the handling and administration of cytotoxic medications, respectively. Conclusion: Cytotoxic chemotherapy is frequently discussed as a treatment option by veterinarians in New Zealand but is currently administered by a smaller proportion. Decisions to use chemotherapy are guided by quality-of-life considerations and adherence to standards of care, while limited knowledge and training hinders its use by other clinicians. Clinical relevance: Chemotherapy is administered less frequently in New Zealand than in the UK. Continuing education and the development of resources that further clinicians' knowledge regarding oncology, chemotherapy, and safe drug handling and administration are needed to support wider adoption in clinical practice.Item Papillomaviruses and Papillomaviral Disease in Dogs and Cats: A Comprehensive Review.(MDPI (Basel, Switzerland), 2024-12-01) Munday JS; Knight CG; Materniak-Kornas M; Rola-Łuszczak M; Woźniakowski GPapillomaviruses (PVs) frequently infect humans as well as non-human species. While most PV infections are asymptomatic, PVs can also cause hyperplastic papillomas (warts) as well as pre-neoplastic and neoplastic lesions. In this review, the life cycle of PVs is discussed, along with the mechanisms by which PVs cause hyperplastic and neoplastic diseases. The humoral and cell-mediated immune responses to PVs are reviewed, giving context to the later discussion on the use of vaccines to reduce canine and feline PV-associated disease. Both dogs and cats are infected by numerous different PV types classified into multiple different PV genera. The taxonomic classification of PVs is reviewed, along with the significance of this classification. The PV-associated diseases of dogs and cats are then described. These descriptions include the clinical presentation of the disease, the causative PV types, the histological features that allow diagnosis, and, where appropriate, possible treatment options. The review is comprehensive and contains the latest information about PVs and the diseases they cause in dogs and cats.Item Multimodal Blockade of the Renin-Angiotensin System in the Treatment of Cancer in Dogs Has Mild Adverse Effects in Some Dogs.(MDPI (Basel, Switzerland), 2024-06-17) Dittmer KE; Wetzel S; Odom T; Munday JS; Flatt EA; Wilson IJ; Hughes C; Tan ST; Ferreira F; Sparger EEThe renin-angiotensin system (RAS) is increasingly being recognized to play a role in the tumor microenvironment, promoting tumor growth. Studies blocking a single part of the RAS have shown mixed results, possibly due to the existence of different bypass pathways and redundancy within the RAS. As such, multimodal blockade of the RAS has been developed to exert more complete inhibition of the RAS. The aim of the present study was to assess the safety of multimodal RAS blockade in dogs. Five dogs (four with appendicular osteosarcoma, one with oral malignant melanoma) were treated with atenolol, benazepril, curcumin, meloxicam, and metformin. The dogs underwent clinical examination, blood pressure measurement, and hematology and serum biochemistry tests performed at 0, 1, 3, 6, 9, and 12 weeks, then every 3 months thereafter. End-of-life decisions were made by the owners. None of the dogs developed hypotension. One dog had intermittent vomiting during the 64 weeks it was on the trial. One dog had a one-off increase in serum SDMA(symmetrical dimethylarginine) concentration. Dogs were euthanized at weeks 3 (osteosarcoma), 10 (osteosarcoma), 17 (osteosarcoma), and 26 (oral malignant melanoma), and one dog was still alive at the end of the trial at 64 weeks (osteosarcoma). This is the first assessment of multimodal blockade of the RAS in dogs, and the results suggest it causes only mild adverse effects in some animals. The efficacy of the treatment was not assessed due to the small number of dogs. This pilot study allows for future larger studies assessing multimodal RAS blockade for the treatment of canine cancer.Item Papillomaviruses in Domestic Cats(MDPI (Basel, Switzerland), 2021-08-22) Munday JS; Thomson NA; Beatty JA; Tasker SPapillomaviruses (PVs) are well established to cause hyperplastic papillomas (warts) in humans and animals. In addition, due to their ability to alter cell regulation, PVs are also recognized to cause approximately 5% of human cancers and these viruses have been associated with neoplasia in a number of animal species. In contrast to other domestic species, cats have traditionally been thought to less frequently develop disease due to PV infection. However, in the last 15 years, the number of viruses and the different lesions associated with PVs in cats have greatly expanded. In this review, the PV life cycle and the subsequent immune response is briefly discussed along with methods used to investigate a PV etiology of a lesion. The seven PV types that are currently known to infect cats are reviewed. The lesions that have been associated with PV infections in cats are then discussed and the review finishes with a brief discussion on the use of vaccines to prevent PV-induced disease in domestic cats.Item Detection of a Novel Papillomavirus Type within a Feline Cutaneous Basal Cell Carcinoma(MDPI (Basel, Switzerland), 2022-12-01) Munday JS; Hunt H; Orbell G; Pfeffer H; Bennett PA 4 cm diameter exophytic mass was excised from the left flank of a 10-year-old domestic short-haired cat. Histology of the superficial aspects of the mass revealed epidermal cells arranged in nests and trabeculae while the deeper parts of the mass consisted of small round cells arranged in sheets or bundles of elongate spindle-shaped cells. A diagnosis of basal cell carcinoma (BCC) was made. Approximately 40% of the cells throughout the neoplasm contained prominent papillomaviral (PV)-induced cell changes. The BCC recurred three months after excision and grew rapidly. At this time a smaller mass was observed on the thorax. Due to the rapid recurrence of the BCC, the cat was euthanatized. As in the initial mass, histology of the recurrent mass revealed pleomorphic cells that often contained PV-induced cell changes. In contrast, the thoracic mass appeared as a more typical BCC and contained no histological evidence of PV infection. A novel PV DNA sequence was amplified from the flank BCC. While the sequence was most (75.1%) similar to Felis catus papillomavirus (FcaPV) 6, the level of similarity between the sequences is consistent with a novel PV type. No PV DNA was amplifiable from the thoracic mass. The case is unique due to the histological features of the BCC and the presence of a putative novel PV type. Observations from the present case add to the number of PV types associated with disease in cats as well as increasing the spectrum of PV-induced lesions in this species.Item Multimodal Blockade of the Renin-Angiotensin System Is Safe and Is a Potential Cancer Treatment for Cats(MDPI (Basel, Switzerland), 2022-08-05) Munday JS; Odom T; Dittmer KE; Wetzel S; Hillmer K; Tan STThe role of the renin-angiotensin system (RAS) in cancer growth and progression is well recognized in humans. However, studies on RAS inhibition with a single agent have not shown consistent anticancer effects, potentially due to the neoplastic cells utilizing alternative pathways for RAS activation. To achieve more complete RAS inhibition, multimodal therapy with several medications that simultaneously block multiple steps in the RAS has been developed for use in humans. In the present study, the safety of multimodal RAS inhibition using atenolol, benazepril, metformin, curcumin, and meloxicam was assessed in six cats with squamous cell carcinomas. Cats were treated for 8 weeks, with blood pressure measured and blood sampled five times during the treatment period. None of the cats developed hypotension, azotemia, or increased serum liver enzyme concentrations. The packed cell volume of one cat decreased to just below the reference range during treatment. One cat was reported to have increased vomiting, although this occurred infrequently. One cat was withdrawn from the study due to difficulties administering the medications, and another cat died of an unrelated cause. Two cats were euthanatized during the study period due to cancer progression. Two cats completed the 8-week study period. One was subsequently euthanized due to cancer progression while the other cat is still alive 32 weeks after entering the study and is still receiving the multimodal blockade of the RAS. This is the first evaluation of multimodal blockade of the RAS in veterinary species. The study showed that the treatment is safe, with only mild adverse effects observed in two treated cats. Due to the small number of cats, the efficacy of treatment could not be evaluated. However, evidence from human studies suggests that a multimodal blockade of RAS could be a safe and cost-effective treatment option for cancer in cats.Item Yeast as a Model to Understand Actin-Mediated Cellular Functions in Mammals-Illustrated with Four Actin Cytoskeleton Proteins(MDPI (Basel, Switzerland), 2020-03-10) Akram Z; Ahmed I; Mack H; Kaur R; Silva RC; Castilho BA; Friant S; Sattlegger E; Munn ALThe budding yeast Saccharomyces cerevisiae has an actin cytoskeleton that comprises a set of protein components analogous to those found in the actin cytoskeletons of higher eukaryotes. Furthermore, the actin cytoskeletons of S. cerevisiae and of higher eukaryotes have some similar physiological roles. The genetic tractability of budding yeast and the availability of a stable haploid cell type facilitates the application of molecular genetic approaches to assign functions to the various actin cytoskeleton components. This has provided information that is in general complementary to that provided by studies of the equivalent proteins of higher eukaryotes and hence has enabled a more complete view of the role of these proteins. Several human functional homologues of yeast actin effectors are implicated in diseases. A better understanding of the molecular mechanisms underpinning the functions of these proteins is critical to develop improved therapeutic strategies. In this article we chose as examples four evolutionarily conserved proteins that associate with the actin cytoskeleton: 1) yeast Hof1p/mammalian PSTPIP1, 2) yeast Rvs167p/mammalian BIN1, 3) yeast eEF1A/eEF1A1 and eEF1A2 and 4) yeast Yih1p/mammalian IMPACT. We compare the knowledge on the functions of these actin cytoskeleton-associated proteins that has arisen from studies of their homologues in yeast with information that has been obtained from in vivo studies using live animals or in vitro studies using cultured animal cell lines.Item Onco-Preventive and Chemo-Protective Effects of Apple Bioactive Compounds(MDPI (Basel, Switzerland), 2021-11) Nezbedova L; McGhie T; Christensen M; Heyes J; Nasef NA; Mehta SCancer is one of the leading causes of death globally. Epidemiological studies have strongly linked a diet high in fruits to a lower incidence of cancer. Furthermore, extensive research shows that secondary plant metabolites known as phytochemicals, which are commonly found in fruits, have onco-preventive and chemo-protective effects. Apple is a commonly consumed fruit worldwide that is available all year round and is a rich source of phytochemicals. In this review, we summarize the association of apple consumption with cancer incidence based on findings from epidemiological and cohort studies. We further provide a comprehensive review of the main phytochemical patterns observed in apples and their bioavailability after consumption. Finally, we report on the latest findings from in vitro and in vivo studies highlighting some of the key molecular mechanisms targeted by apple phytochemicals in relation to inhibiting multiple ‘hallmarks of cancer’ that are important in the progression of cancer.Item Lung cancer risk in painters: results from the SYNERGY pooled case-control study consortium(BMJ Publishing Group Ltd, 2021-04) Guha N; Bouaoun L; Kromhout H; Vermeulen R; Brüning T; Behrens T; Peters S; Luzon V; Siemiatycki J; Xu M; Kendzia B; Guenel P; Luce D; Karrasch S; Wichmann H-E; Consonni D; Landi MT; Caporaso NE; Gustavsson P; Plato N; Merletti F; Mirabelli D; Richiardi L; Jöckel K-H; Ahrens W; Pohlabeln H; TSE LA; Yu IT-S; Tardón A; Boffetta P; Zaridze D; 't Mannetje A; Pearce N; Davies MPA; Lissowska J; Świątkowska B; McLaughlin J; Demers PA; Bencko V; Foretova L; Janout V; Pándics T; Fabianova E; Mates D; Forastiere F; Bueno-de-Mesquita B; Schüz J; Straif K; Olsson AOBJECTIVES: We evaluated the risk of lung cancer associated with ever working as a painter, duration of employment and type of painter by histological subtype as well as joint effects with smoking, within the SYNERGY project. METHODS: Data were pooled from 16 participating case-control studies conducted internationally. Detailed individual occupational and smoking histories were available for 19 369 lung cancer cases (684 ever employed as painters) and 23 674 age-matched and sex-matched controls (532 painters). Multivariable unconditional logistic regression models were adjusted for age, sex, centre, cigarette pack-years, time-since-smoking cessation and lifetime work in other jobs that entailed exposure to lung carcinogens. RESULTS: Ever having worked as a painter was associated with an increased risk of lung cancer in men (OR 1.30; 95% CI 1.13 to 1.50). The association was strongest for construction and repair painters and the risk was elevated for all histological subtypes, although more evident for small cell and squamous cell lung cancer than for adenocarcinoma and large cell carcinoma. There was evidence of interaction on the additive scale between smoking and employment as a painter (relative excess risk due to interaction >0). CONCLUSIONS: Our results by type/industry of painter may aid future identification of causative agents or exposure scenarios to develop evidence-based practices for reducing harmful exposures in painters.